Skip to main content
SpringerLink
Log in

EU Commission pharma policy change risky

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. SANCO Unit D5 (Medicinal Products–Authorisations, European Medicines Agency) and Unit D6 (Medicinal Products–Quality, Safety and Efficacy)

References

  1. Health Action International (HAI). Public health in danger with move of pharmaceutical policy to DG Enterprise and Industry. Internet Document : 12 Sep 2014. Available from: URL: http://haieurope.org/wp-content/uploads/2014/09/Statement-PH-in-danger-with-move-of-pharma-policy-to-Enterprise.pdf

  2. Murray J. A bad start for the new Commission. Internet Document : 11 Sep 2014. Available from: URL: http://www.euractiv.com/sections/health-consumers/bad-start-new-commission-308376

  3. EUROPA. The Juncker Commission: A strong and experienced team standing for change. Internet Document : 10 Sep 2014. Available from: URL: http://europa.eu/rapid/press-release_IP-14-984_en.htm

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

EU Commission pharma policy change risky. Reactions Weekly 1519, 8 (2014). https://doi.org/10.1007/s40278-014-3427-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-014-3427-4

Search

Navigation